Compliance with Primary Malaria Chemoprophylaxis: Is Weekly Prophylaxis Better Than Daily Prophylaxis?

References

• World Health Organization. World Malaria Report 2019. Geneva, Switzerland: WHO; 2020.
   Google Scholar
• Fernando SD, Ranaweera D, Weerasena MS, et al. Success of malaria chemoprophylaxis for outbound civil and military travellers in prevention of reintroduction of malaria in Sri Lanka. Int Health. 2020;12(4):332–338. doi:10.1093/inthealth/ihz094
   Web of Science ®Google Scholar
• Fernando SD, Rodrigo C, Rajapakse S. Chemoprophylaxis in malaria: drugs, evidence of efficacy and costs. Asian Pac J Trop Med. 2011;4(4):330–336. doi:10.1016/S1995-7645(11)60098-9
   Web of Science ®Google Scholar
• Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg. 2006;75(3):402–415. doi:10.4269/ajtmh.2006.75.402
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. CDC Yellow Book: Health Information for International Travel. New York: Oxford University Press; 2020.
   Google Scholar
• Rodrigo C, Rajapakse S, Fernando SD. Tafenoquine for primary and terminal prophylaxis of malaria in apparently healthy people: a systematic review. Trans R Soc Trop Med Hyg. 2019;113(10):579–586. doi:10.1093/trstmh/trz052
   Web of Science ®Google Scholar
• Lau CL, Ramsey L, Mills LC, Furuya-Kanamori L, Mills DJ. Drug-free holidays: compliance, tolerability, and acceptability of a 3-day atovaquone/proguanil schedule for pretravel malaria chemoprophylaxis in australian travelers. Clin Infect Dis. 2019;69(1):137–143. doi:10.1093/cid/ciy854
   PubMed Web of Science ®Google Scholar
• Baird JK, Lacy MD, Basri H, et al. Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis. 2001;33(12):1990–1997. doi:10.1086/324085
   Web of Science ®Google Scholar
• Camus D, Djossou F, Schilthuis HJ, et al. Atovaquone-proguanil versus chloroquine- proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study. Clin Infect Dis. 2004;38(12):1716–1723. doi:10.1086/421086
   Web of Science ®Google Scholar
• Croft AM, Clayton TC, World MJ. Side effects of mefloquine prophylaxis for malaria: an independent randomized controlled trial. Trans R Soc Trop Med Hyg. 1997;91(2):199–203. doi:10.1016/S0035-9203(97)90223-6
   PubMed Web of Science ®Google Scholar
• Fernando D, de Silva D, Carter R, Mendis KN, Wickremasinghe R. A randomized, double-blind, placebo-controlled, clinical trial of the impact of malaria prevention on the educational attainment of school children. Am J Trop Med Hyg. 2006;74(3):386–393. doi:10.4269/ajtmh.2006.74.386
   Web of Science ®Google Scholar
• Ling J, Baird JK, Fryauff DJ, et al. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Clin Infect Dis. 2002;35(7):825–833. doi:10.1086/342578
   Web of Science ®Google Scholar
• Michel R, Bardot S, Queyriaux B, Boutin JP, Touze JE. Doxycycline-chloroquine vs. doxycycline-placebo for malaria prophylaxis in nonimmune soldiers: a double-blind randomized field trial in sub-Saharan Africa. Trans R Soc Trop Med Hyg. 2010;104(4):290–297. doi:10.1016/j.trstmh.2009.10.001
   PubMed Web of Science ®Google Scholar
• Nasveld PE, Edstein MD, Brennan L, et al. Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. Antimicrob Agents Chemother. 2010;54(2):792–798. doi:10.1128/AAC.00354-09
   PubMed Web of Science ®Google Scholar
• Ohrt C, Richie TL, Widjaja H, et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo- controlled trial. Ann Intern Med. 1997;126(12):963–972. doi:10.7326/0003-4819-126-12-199706150-00006
   Web of Science ®Google Scholar
• Soto J, Toledo J, Luzz M, Gutierrez P, Berman J, Duparc S. Randomized, double-blind, placebo-controlled study of Malarone for malaria prophylaxis in non-immune Colombian soldiers. Am J Trop Med Hyg. 2006;75(3):430–433. doi:10.4269/ajtmh.2006.75.430
   Web of Science ®Google Scholar
• Fontanet AL, Houze S, Keundjian A, et al. Efficacy of antimalarial chemoprophylaxis among French residents travelling to Africa. Trans R Soc Trop Med Hyg. 2005;99(2):91–100. doi:10.1016/j.trstmh.2004.01.006
   Web of Science ®Google Scholar
• Ben-Ami R, Siegman-Igra Y, Anis E, et al. Malaria in travelers returning from short organized tours to holiday resorts in Mombassa, Kenya. Isr Med Assoc J. 2005;7(6):364–367.
   Web of Science ®Google Scholar
• National Institutes of Health. Study quality assessment tools; 2020. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Accessed August 15, 2020.
   Google Scholar
• Laver SM, Wetzels J, Behrens RH. Knowledge of malaria, risk perception, and compliance with prophylaxis and personal and environmental preventive measures in travelers exiting Zimbabwe from Harare and Victoria Falls International airport. J Travel Med. 2001;8(6):298–303. doi:10.2310/7060.2001.23975
   PubMed Web of Science ®Google Scholar
• Lobel HO, Baker MA, Gras FA, et al. Use of malaria prevention measures by North American and European travelers to East Africa. J Travel Med. 2001;8(4):167–172. doi:10.2310/7060.2001.22206
   Web of Science ®Google Scholar
• Sanchez JL, Bendet I, Grogl M, et al. Malaria in Brazilian military personnel deployed to Angola. J Travel Med. 2000;7(5):275–282. doi:10.2310/7060.2000.00077
   Web of Science ®Google Scholar
• Frickmann H, Schwarz NG, Holtherm HU, et al. Compliance with antimalarial chemoprophylaxis in German soldiers: a 6-year survey. Infection. 2013;41(2):311–320. doi:10.1007/s15010-013-0411-5
   Web of Science ®Google Scholar
• Landman KZ, Tan KR, Arguin PM. Adherence to malaria prophylaxis among Peace Corps Volunteers in the Africa region, 2013. Travel Med Infect Dis. 2015;13(1):61–68.
   Web of Science ®Google Scholar
• Saunders DL, Garges E, Manning JE, et al. Safety, tolerability, and compliance with long-term antimalarial chemoprophylaxis in American Soldiers in Afghanistan. Am J Trop Med Hyg. 2015;93(3):584–590. doi:10.4269/ajtmh.15-0245
   Web of Science ®Google Scholar
• Matsumura T, Fujii T, Miura T, et al. Questionnaire-based analysis of mefloquine chemoprophylaxis for malaria in a Japanese population. J Infect Chemother. 2005;11(4):196–198. doi:10.1007/s10156-005-0390-2
   Google Scholar
• Belderok SM, van den Hoek A, Roeffen W, Sauerwein R, Sonder GJB. Adherence to chemoprophylaxis and plasmodium falciparum anti-circumsporozoite seroconversion in a prospective cohort study of Dutch Short-Term Travelers. PLoS One. 2013;8(2):e56863. doi:10.1371/journal.pone.0056863
   Web of Science ®Google Scholar
• Fujii T, Kaku K, Jelinek T, Kimura M. Malaria and mefloquine prophylaxis use among Japan ground self-defense force personnel deployed in East Timor. J Travel Med. 2007;14(4):226–232. doi:10.1111/j.1708-8305.2007.00122.x
   Web of Science ®Google Scholar
• Peragallo MS, Sarnicola G, Boccolini D, Romi R, Mammana G. Risk assessment and prevention of malaria among Italian troops in Afghanistan, 2002 to 2011. J Travel Med. 2014;21(1):24–32. doi:10.1111/jtm.12046
   Web of Science ®Google Scholar
• Tan KR, Henderson SJ, Williamson J, et al. Long term health outcomes among returned peace corps volunteers after malaria prophylaxis, 1995–2014. Travel Med Infect Dis. 2017;17:50–55. doi:10.1016/j.tmaid.2017.05.003
   Web of Science ®Google Scholar
• Landry P, Iorillo D, Darioli R, Burnier M, Genton B. Do travelers really take their mefloquine malaria chemoprophylaxis? Estimation of adherence by an electronic pillbox. J Travel Med. 2006;13(1):8–14. doi:10.1111/j.1708-8305.2006.00005.x
   Web of Science ®Google Scholar
• Petersen E, Ronne T, Ronn A, Bygbjerg I, Larsen SO. Reported side effects to chloroquine, chloroquine plus proguanil, and mefloquine as chemoprophylaxis against malaria in Danish travelers. J Travel Med. 2000;7(2):79–84. doi:10.2310/7060.2000.00026
   Web of Science ®Google Scholar
• Hoebe C, de Munter J, Thijs C. Adverse effects and compliance with mefloquine or proguanil antimalarial chemoprophylaxis. Eur J Clin Pharmacol. 1997;52(4):269–275. doi:10.1007/s002280050288
   Web of Science ®Google Scholar
• Hoefnagel JGM, Massar K, Hautvast JLA. Non-adherence to malaria prophylaxis: the influence of travel-related and psychosocial factors. J Infect Public Health. 2020;13(4):532–537. doi:10.1016/j.jiph.2019.10.004
   Web of Science ®Google Scholar
• Rodrigues KMD, da Costa ABF, Santoro-Lopes G. Adherence to malaria prophylaxis among travelers from a middle-income country. Rev Soc Bras Med Trop. 2019;52. doi:10.1590/0037-8682-0014-2019
   Web of Science ®Google Scholar
• Mavrogordato A, Lever AM. A cluster of Plasmodium vivax malaria in an expedition group to Ethiopia: prophylactic efficacy of atovaquone/proguanil on liver stages of P. vivax. J Infect. 2012;65(3):269–274. doi:10.1016/j.jinf.2012.04.015
   Web of Science ®Google Scholar
• Goodyer L, Rice L, Martin A. Choice of and adherence to prophylactic antimalarials. J Travel Med. 2011;18(4):245–249. doi:10.1111/j.1708-8305.2011.00534.x
   Web of Science ®Google Scholar
• Shady I. Determinants of adherence with malaria chemoprophylactic drugs used in a traveler’s health clinic. J Trop Med. 2015;2015:163716. doi:10.1155/2015/163716
   Google Scholar
• Sonmez A, Harlak A, Kilic S, et al. The efficacy and tolerability of doxycycline and mefloquine in malaria prophylaxis of the ISAF troops in Afghanistan. J Infect. 2005;51(3):253–258. doi:10.1016/j.jinf.2005.01.014
   Web of Science ®Google Scholar
• Petersen E. The safety of atovaquone/proguanil in long-term malaria prophylaxis of nonimmune adults. J Travel Med. 2003;10(SUPPL.1):S13–S15. doi:10.2310/7060.2003.35050
   Google Scholar
• DePetrillo JC, Singer C, Bergagnini IA, Kolakowski P, Edwards B, Smith MA. Assessment of adherence to atovaquone-proguanil prophylaxis in travelers. J Travel Med. 2010;17(4):217–220. doi:10.1111/j.1708-8305.2010.00426.x
   Web of Science ®Google Scholar
• Nicosia V, Colombo G, Consentino M, et al. Assessment of acceptability and ease of use of atovaquone/proguanil medication in subjects undergoing malaria prophylaxis. Ther Clin Risk Manag. 2008;4(5):1105–1110. doi:10.2147/TCRM.S3782
   PubMedGoogle Scholar
• Bellanger AP, Faucher JF, Robedat P, Schmitt A, Millon L, Hoen B. Malaria outbreak in French troops returning from Cote d’Ivoire. Scand J Infect Dis. 2011;43(3):230–233. doi:10.3109/00365548.2010.538857
   PubMed Web of Science ®Google Scholar
• Grabias B, Kumar S. Adverse neuropsychiatric effects of antimalarial drugs. Expert Opin Drug Saf. 2016;15(7):903–910. doi:10.1080/14740338.2016.1175428
   PubMed Web of Science ®Google Scholar
• Fryauff D, Baird K, Basri H, et al. Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet. 1995;346(8984):1190–1193. doi:10.1016/S0140-6736(95)92898-7
   Web of Science ®Google Scholar
• Frampton JE. Tafenoquine: first global approval. Drugs. 2018;78(14):1517–1523. doi:10.1007/s40265-018-0979-2
   PubMed Web of Science ®Google Scholar